search
Back to results

Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom

Primary Purpose

Vitamin D Deficiency, Metabolic Syndrome, Prediabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Mushroom with 600 IU vitamin D2
Mushroom with 4000 IU Vitamin D2
600 IU Vitamin D3 and untreated mushroom
4000 IU Vitamin D3 and untreated mushroom
Placebo
Sponsored by
Icahn School of Medicine at Mount Sinai
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vitamin D Deficiency focused on measuring Vitamin D, Mushroom, Cholecalciferol, Prediabetes, Metabolic Syndrome

Eligibility Criteria

30 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult non-smoking subjects from ages 30 to 90, any race or gender
  • Presence of at least two of the following characteristics:

    • Waist circumference:

Men: > 102 cm Women: > 88 cm

  • Blood pressure: > 130/85 mm Hg (or use of anti-BP medication)
  • HDL-cholesterol:

Men: < 40 mg/dL Women: < 50 mg/dL

  • Triglycerides: > 150 mg/dL (or use of medications for high triglycerides such as fibrates or nicotinic acid)
  • Fasting blood sugar > 100 mg/dl (or use of metformin), but a HbA1c < 6.5%

Exclusion Criteria:

  • Blood levels of 25(OH)D > 50 nmol/L
  • Regular intake of vitamin D fortified milk exceeding approximately 3 glasses/day
  • Lack of the ability to comprehend instructions and/or sign the consent form
  • Inability to comply with the potential requirement to eat a daily portion of provided mushroom together with meals
  • Inability to comply with the rule of avoiding any beach days during the duration of the study
  • Any projected trip to sunny places such as Puerto Rico and the Caribbean during the period of study
  • Any attendance to tanning studios during the period of study
  • Women who regularly use a veil over their heads
  • Any history of kidney stone formation
  • Non-traumatic bone fracture over the past 3 years
  • Any form of vitamin D supplement intake, including combined calcium and vitamin D products
  • Active smoking

Sites / Locations

  • Icahn School of Medicine at Mount Sinai

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Mushroom with 600 IU vitamin D2

Mushroom with 4000 IU Vitamin D2

600 IU Vitamin D3 and untreated mushroom

4000 IU Vitamin D3 and untreated mushroom

Arm Description

Mushroom with 600 IU of vitamin D2 daily and placebo tablet

Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet

Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom

Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom

Outcomes

Primary Outcome Measures

25OH Vitamin D level
To compare the efficacy of two different doses of vitamin D2 (600 or 4000 IU/day) provided by Vitamin D2 fortified mushrooms added to one of the daily meals versus same doses of vitamin D3 provided as oral supplements in reaching adequate or optimal circulating levels of 25(OH) D in a racially diverse group of subjects with Vitamin D deficiency and pre-diabetes or the metabolic syndrome.

Secondary Outcome Measures

Serum calcium
To assess the safety of the intervention with respect to serum calcium levels in all study subjects. Measured at each study visit (1, 2, 3, and 4 months)
Serum calcium
To assess the safety of the intervention with respect to serum calcium levels in all study subjects. Measured at each study visit (1, 2, 3, and 4 months)
Serum calcium
To assess the safety of the intervention with respect to serum calcium levels in all study subjects. Measured at each study visit (1, 2, 3, and 4 months)
Serum calcium
To assess the safety of the intervention with respect to serum calcium levels in all study subjects. Measured at each study visit (1, 2, 3, and 4 months)
Markers of inflammation and metabolic control
To demonstrate and compare the effect of the intervention with above two doses of vitamin D on circulating levels of markers of inflammation and metabolic control (CRP, tumor necrosis factor (TNF), hemoglobin A1c, insulin, blood glucose, lipids).

Full Information

First Posted
December 6, 2011
Last Updated
April 12, 2017
Sponsor
Icahn School of Medicine at Mount Sinai
search

1. Study Identification

Unique Protocol Identification Number
NCT01488734
Brief Title
Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom
Official Title
Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Icahn School of Medicine at Mount Sinai

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the safety and efficacy of two different amounts of vitamin D2 (600 or 4000 International Units/day) provided by mushrooms added to one of the daily meals versus same doses of vitamin D3 provided as oral supplements sold in any drugstore in reaching adequate or optimal blood levels of 25(OH)D in people with Vitamin D deficiency and pre-diabetes (high blood sugar without full blown diabetes) or the metabolic syndrome. Metabolic syndrome is the name of a group of risk factors that raise the risk for heart disease and other health problems, such as diabetes and stroke as described by the US department of Health and Human Services. This study will also attempt to demonstrate and compare the effect of the intervention with above two doses of vitamin D on blood levels of tests that show inflammation.
Detailed Description
Poor vitamin D status is now considered epidemic in North America. In addition to its effects on bone metabolism, Vitamin D has several other important biological effects including modulating the immune system, stimulating the production of insulin and decreasing renin production in the kidney. Furthermore, the active metabolite of vitamin D, 1,25 dihydroxyvitamin D (1,25(OH)2D), is a very potent inhibitor of cellular proliferation and inducer of terminal differentiation and vitamin D deficiency has been associated with higher prevalence of cancer, autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, type 1 diabetes and hypertension. The current recommendations for dietary vitamin D in North America are much too low to maintain optimal levels of 25(OH)D associated with disease prevention. The majority of circulating 25(0H) D originates from cutaneous synthesis upon exposure to adequate sunlight. However, seasonal changes, living at high latitudes or low polluted altitudes, dark skin pigmentation and aging are among the many factors that can impede this process requiring periodic reliance on dietary sources to supply the precursor to 25(OH)D. In November of 2010, the Institute of Medicine (IOM) of the National Academy of Science established new DRI values for vitamin: EAR (Estimated Average Requirement) of 400 IU (10 µg; RDA ( Recommended Daily Intake) of 600 IU (15µg) for adults up to 70 years of age, and an UL of 4000 IU (50µg) (21). The IOM also discourages the taking of dietary supplements to achieve the RDA for vitamin D and encourages Americans to achieve their needed vitamin D through food sources. The proposed study will be to provide meals with one serving of fresh mushroom per day that could have two different levels of vitamin D2 in it (600 IU or 4,000 IU/day, which are the 2011 currently recommended RDA to age 70 AI and UL, respectively) for four months and test both the bioavailability of vitamin D in mushroom, as reflected in blood 25(OH)D levels, as well as the effect of vitamin D on markers of disease (e.g. C-reactive protein (CRP), Hemoglobin A1c, etc). The vitamin D2 amount in mushrooms can easily be manipulated just by adjusting the time and distance of their UVB exposure. Two groups will be compared with controls who will receive the same dose of vitamin D3 in the form of tablets commercially available (600 IU or 4000 IU/day).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency, Metabolic Syndrome, Prediabetes
Keywords
Vitamin D, Mushroom, Cholecalciferol, Prediabetes, Metabolic Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
47 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mushroom with 600 IU vitamin D2
Arm Type
Experimental
Arm Description
Mushroom with 600 IU of vitamin D2 daily and placebo tablet
Arm Title
Mushroom with 4000 IU Vitamin D2
Arm Type
Experimental
Arm Description
Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet
Arm Title
600 IU Vitamin D3 and untreated mushroom
Arm Type
Active Comparator
Arm Description
Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom
Arm Title
4000 IU Vitamin D3 and untreated mushroom
Arm Type
Active Comparator
Arm Description
Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom
Intervention Type
Dietary Supplement
Intervention Name(s)
Mushroom with 600 IU vitamin D2
Intervention Description
Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
Intervention Type
Dietary Supplement
Intervention Name(s)
Mushroom with 4000 IU Vitamin D2
Intervention Description
Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
Intervention Type
Dietary Supplement
Intervention Name(s)
600 IU Vitamin D3 and untreated mushroom
Intervention Description
Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
Intervention Type
Dietary Supplement
Intervention Name(s)
4000 IU Vitamin D3 and untreated mushroom
Intervention Description
Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo for the fortified mushroom arms
Primary Outcome Measure Information:
Title
25OH Vitamin D level
Description
To compare the efficacy of two different doses of vitamin D2 (600 or 4000 IU/day) provided by Vitamin D2 fortified mushrooms added to one of the daily meals versus same doses of vitamin D3 provided as oral supplements in reaching adequate or optimal circulating levels of 25(OH) D in a racially diverse group of subjects with Vitamin D deficiency and pre-diabetes or the metabolic syndrome.
Time Frame
at 4 months
Secondary Outcome Measure Information:
Title
Serum calcium
Description
To assess the safety of the intervention with respect to serum calcium levels in all study subjects. Measured at each study visit (1, 2, 3, and 4 months)
Time Frame
at 1 month
Title
Serum calcium
Description
To assess the safety of the intervention with respect to serum calcium levels in all study subjects. Measured at each study visit (1, 2, 3, and 4 months)
Time Frame
at 2 months
Title
Serum calcium
Description
To assess the safety of the intervention with respect to serum calcium levels in all study subjects. Measured at each study visit (1, 2, 3, and 4 months)
Time Frame
at 3 months
Title
Serum calcium
Description
To assess the safety of the intervention with respect to serum calcium levels in all study subjects. Measured at each study visit (1, 2, 3, and 4 months)
Time Frame
at 4 months
Title
Markers of inflammation and metabolic control
Description
To demonstrate and compare the effect of the intervention with above two doses of vitamin D on circulating levels of markers of inflammation and metabolic control (CRP, tumor necrosis factor (TNF), hemoglobin A1c, insulin, blood glucose, lipids).
Time Frame
at 4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult non-smoking subjects from ages 30 to 90, any race or gender Presence of at least two of the following characteristics: Waist circumference: Men: > 102 cm Women: > 88 cm Blood pressure: > 130/85 mm Hg (or use of anti-BP medication) HDL-cholesterol: Men: < 40 mg/dL Women: < 50 mg/dL Triglycerides: > 150 mg/dL (or use of medications for high triglycerides such as fibrates or nicotinic acid) Fasting blood sugar > 100 mg/dl (or use of metformin), but a HbA1c < 6.5% Exclusion Criteria: Blood levels of 25(OH)D > 50 nmol/L Regular intake of vitamin D fortified milk exceeding approximately 3 glasses/day Lack of the ability to comprehend instructions and/or sign the consent form Inability to comply with the potential requirement to eat a daily portion of provided mushroom together with meals Inability to comply with the rule of avoiding any beach days during the duration of the study Any projected trip to sunny places such as Puerto Rico and the Caribbean during the period of study Any attendance to tanning studios during the period of study Women who regularly use a veil over their heads Any history of kidney stone formation Non-traumatic bone fracture over the past 3 years Any form of vitamin D supplement intake, including combined calcium and vitamin D products Active smoking
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jaime Uribarri, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Bioavailability and Biological Effects of Vitamin D2 Contained in Mushroom

We'll reach out to this number within 24 hrs